Immuron Ltd — Regulatory Filings 2007

Mar 19, 2007

Company announcement

Final EV-71 antibodies highly effective Ouality control results, dosage size and packaging update

Tuesday 20 March 2007

Anadis (ASX:ANX) today announced that it has completed the quality control (OC) analysis of the colostrum containing high levels of Enterovirus-71 antibodies for the company's EV-71 preventative.

The samples from the initial processed product show highly effective neutralisation of the Enterovirus 71 virus in laboratory analysis.

Approximately 19,000 litres of liquid colostrum is to be processed. It is anticipated that this will produce almost 1.600 kilograms of Enterovirus-71 antibody-rich colostrum. This has the capability to produce more than 10.5 million doses of the preventative due to the high efficacy of the antibodies.

The product is designed to be used during the high-risk season and will be sold in packages containing 30 sachets. Anadis has the potential to produce more than 350.000 packages of the preventative, to be marketed as an export-only product under the trade name EVProtec.

This result is a credit to the dedicated scientific team and clearly demonstrates Anadis' ability to deliver antibodies against a virus from a laboratory scale up to a commercially viable product. Animal efficacy trials are progressing well and results will be released to market upon completion.

For further information, please contact:

Arie Nudel – Investor Relations

Email: $\arctan(\alpha)$ anadis.com.au Tel: +61 3 9358 6388

Dr Grant Rawlin – Head of $R&D$ Email: grant.r@anadis.com.au Tel: +61 3 9358 6388

Richard Allen - Media

Email: richard@oxygenpr.com.au, Tel: +61 3 9915 6341

About Anadis Limited:

Anadis, a Melbourne-based biopharmaceutical company, is focused on Nutraceutical and Pharmaceutical research and development. Anadis is a specialist in the development of dairy (bovine) colostrum-derived products for therapeutic use in humans. Projects include:

Anadis' first commercialised product: Travelan is a natural product, which significantly decreases the risk of the medical condition known as Travellers Diarrhoea and the symptoms of gastrointestinal disorders. Travelan is a colostrum preparation, against the common strains of E, coli – the most common cause of Travellers Diarrhoea.

Travelan, which has been approved for distribution in North America, now has US and Canadian distributors appointed. Travelan distribution is currently being developed for other markets including: Singapore, India. Korea, United Arab Emirates. Thailand, Malaysia, South Africa and the UK and EU.

Travelan has recently been potentially identified for additional gastrointestinal indications including Irritable Bowel Syndrome and Inflammatory Bowel Disorder.

For more information please visit www.travelan.com

$EV-71$ – a bioactive protein based preventative product against Enterovirus 71, a debilitating polio-like disease – is one of the viruses that causes 'hand, foot and mouth' or 'slapped cheek' disease. A significant proportion of younger children effected can develop nervous signs such as fits and paralysis. Enterovirus $71$ can be fatal. Anadis is preparing colostrum antibodies for commercialisation in an anti-EV71 preventative, set to begin marketing in Taiwan during the northern hemisphere summer of 2007.

A set of Bio-Defence and Respiratory Protection technologies – a project in conjunction with the Australian Department of Defence and US Bio-Defence Organisations – initially focused on short-term immediate protection from airborne bacteria such as anthrax and plague. Future civilian applications include hay fever and asthma.

This project is expanding to examine the use of antibodies in providing respiratory protection against Influenza virus.

Bio-Shield 10 a range of bio-shielding technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the pro-biotic market.

Development into an Immune Stimulating Infant Formula is underway, initially destined for the Asian market.

Pyloran, which has been clinically proven to reduce levels of H. pylori bacteria in the stomach and reduce the symptoms of H, pylori associated gastritis. Anadis is also in early development of an $H$ . pylori vaccine.

Anadis - Delivering on the Promise of Biotechnology

Visit our websites: www.anadis.com.au and www.travelan.com